{"filing":{"accession_number":"0001104659-26-066956","cik":"0001787297","ticker":"PASG","company_name":"Passage BIO, Inc.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"pasg-20260521x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1787297/000110465926066956/pasg-20260521x8k.htm"},"events":[{"id":8677,"run_id":7620,"accession_number":"0001104659-26-066956","anchor_item_number":"1.02","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The filing discloses termination of two material definitive agreements: (1) the Gemma Collaboration Agreement involving research and license rights for Huntington's disease and Temporal Lobe Epilepsy programs, and (2) the 2005 Market Street Lease Agreement with a $2.3 million termination fee. While Item 1.02 is titled \"Termination of a Material Definitive Agreement,\" neither termination fits cleanly into the specific event taxonomy (not M\u0026A, not covenant breach, not litigation). The Gemma termination is particularly material as it affects active R\u0026D programs in CNS indications, and the lease termination involves a significant cash outlay. This is best classified as other_material given the absence of a more specific category for strategic collaboration or lease terminations.","company_name":"Passage BIO, Inc.","ticker":"PASG","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":1820,"accession_number":"0001104659-26-066956","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses termination of two material definitive agreements: (1) the Gemma Collaboration Agreement involving research and license rights for Huntington's disease and Temporal Lobe Epilepsy programs, and (2) the 2005 Market Street Lease Agreement with a $2.3 million termination fee. While Item 1.02 is titled \"Termination of a Material Definitive Agreement,\" neither termination fits cleanly into the specific event taxonomy (not M\u0026A, not covenant breach, not litigation). The Gemma termination is particularly material as it affects active R\u0026D programs in CNS indications, and the lease termination involves a significant cash outlay. This is best classified as other_material given the absence of a more specific category for strategic collaboration or lease terminations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:09:45.758372+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1820,"accession_number":"0001104659-26-066956","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses termination of two material definitive agreements: (1) the Gemma Collaboration Agreement involving research and license rights for Huntington's disease and Temporal Lobe Epilepsy programs, and (2) the 2005 Market Street Lease Agreement with a $2.3 million termination fee. While Item 1.02 is titled \"Termination of a Material Definitive Agreement,\" neither termination fits cleanly into the specific event taxonomy (not M\u0026A, not covenant breach, not litigation). The Gemma termination is particularly material as it affects active R\u0026D programs in CNS indications, and the lease termination involves a significant cash outlay. This is best classified as other_material given the absence of a more specific category for strategic collaboration or lease terminations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:09:45.758372+00:00","company_name":"Passage BIO, Inc.","ticker":"PASG","filing_date":"2026-05-27"}]}